Oct 15, 2026 08:00AM
Oct 15, 2026 08:00AM
Aug 11, 2026 08:00AM
May 18, 2026 08:00AM
May 15, 2026 07:00AM
May 15, 2026 07:00AM
May 13, 2026 08:00AM Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
Apr 27, 2026 04:05PM
Apr 27, 2026 04:05PM
Mar 10, 2026 08:00AM
Feb 23, 2026 05:06PM
Feb 23, 2026 05:05PM
Jan 22, 2026 08:00AM
Jan 22, 2026 08:00AM Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
Jan 12, 2026 07:01AM
Jan 12, 2026 07:00AM
Jan 7, 2026 08:01AM
Jan 7, 2026 08:00AM
Jan 7, 2026 03:46AM
Jan 5, 2026 08:01AM
Jan 5, 2026 08:00AM Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations
Dec 3, 2025 08:00AM
Dec 3, 2025 08:00AM
Dec 1, 2025 04:15PM
Dec 1, 2025 04:15PM
Nov 20, 2025 06:41AM
Nov 19, 2025 08:00AM
Nov 19, 2025 08:00AM Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
Nov 18, 2025 04:30PM
Nov 18, 2025 04:30PM
Nov 17, 2025 08:00AM
Nov 17, 2025 08:00AM
Nov 10, 2025 08:00AM
Aug 11, 2025 08:00AM
Jun 30, 2025 08:10AM Protara Therapeutics (TARA) Announces Addition to the Russell 3000 Index
Jun 30, 2025 08:00AM
Jun 2, 2025 04:04PM
Jun 2, 2025 04:04PM
May 8, 2025 08:00AM
Apr 28, 2025 12:32PM
Apr 26, 2025 10:00AM
Apr 23, 2025 08:00AM Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025
Apr 15, 2025 04:14PM
Apr 15, 2025 04:13PM
Apr 10, 2025 04:07PM
Apr 10, 2025 04:05PM
Mar 19, 2025 08:03AM
Mar 19, 2025 08:00AM
Mar 5, 2025 08:00AM Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Jan 13, 2025 08:00AM

335,223 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All